Similar Papers

Paper Title
Journal
Date
Author
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A Sallman ... Paresh Vyas
Blood | VOL. 134
David A Sallman, et. al.David A Sallman ... Paresh Vyas
13 Nov 2019
Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia
Jifeng Yu ... Zhongxing Jiang
Experimental Hematology & Oncology | VOL. 9
Jifeng Yu, et. al.Jifeng Yu ... Zhongxing Jiang
06 Jan 2020
6. Genetic characterization of tetraploid/near-tetraploid acute myeloid leukemia patients
Matthew Avenarius ... Lynne Abruzzo
Cancer Genetics | VOL. 252-253
Matthew Avenarius, et. al.Matthew Avenarius ... Lynne Abruzzo
23 Mar 2021
Molecular Profiling of Decitabine Response in MDS and AML Patients
Pawan Kumar Upadhyay ... John Welch
Blood | VOL. 136
Pawan Kumar Upadhyay, et. al.Pawan Kumar Upadhyay ... John Welch
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
The dark zone of CNS relapse in DLBCL
Kieron Dunleavy
Blood | VOL. 145
Kieron DunleavyKieron Dunleavy
06 Feb 2025
Impact of new medications on the treatment of Immune TTP.
Marie Scully ... William A Lester
Blood | VOL. -
Marie Scully, et. al.Marie Scully ... William A Lester
06 Feb 2025
No exit: targeting RNA export in T-cell malignancy
Katherine L B Borden
Blood | VOL. 145
Katherine L B BordenKatherine L B Borden
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.